Praxis Bioresearch Presents Phase 0 Clinical Data for PRX-P4-003 at 14th Annual CTAD conference LOS ANGELES, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Praxis Bioresearch reports Clinical Phase 0 study data (PBR001) to demonstrate the desired pharmacokinetic profile for its lead product candidate,...

Praxis Bioresearch Announces Positive Results from Clinical Microdose Study in Humans Showing Oral Activation of Its Novel Prodrug Stimulant PRX-P4-003 All subjects who were dosed with Prodrug PRX-P4-003 had systemic exposure of the active moiety (-)-fencamfamine suggesting robust intestinal conversionAs anticipated, fed subjects showed earlier...